Letters

Author Affiliations: University of California, Davis (Cohen); University of Colorado, Boulder, Colorado, USA (Louie); Seres Therapeutics, Cambridge, Massachusetts (McGovern).

Corresponding Author: Barbara H. McGovern, MD, Seres Therapeutics, 202 Sidney St, Cambridge, MA 02139 (bmcgov@serestherapeutics.com).

Conflict of Interest Disclosures: Dr Louie reported receiving grants from Seres Therapeutics, Rebiotix Ferring, Finch Therapeutics, and Vedanta Biosciences during the conduct of the study and grants from Summit PLC and Crestone outside the submitted work. Dr McGovern reported receiving personal fees from Seres Therapeutics as an employee and stockholder. No other disclosures were reported.


CORRECTION

Incorrect Data in Abstract and Figure: In the Original Investigation titled “Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Afibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy,” published in the February 7, 2023, issue of JAMA, 3 items were published incorrectly. In the Abstract, the severity level of 43 to 53 for the Early Treatment Diabetic Retinopathy Study (ETDRS) was correct, but it should not have shown a range explaining best and worst scores. A comma was inserted into the Conclusion sections of the Abstract and the text to clarify meaning: “Among patients with NPDR but without DME, at 4 years treatment with afibercept vs sham, initiating afibercept treatment only if vision-threatening complications developed, resulted in statistically significant anatomic improvement but no improvement in visual acuity.” In Figure 1, numeric values indicating inclusion in the per-protocol analyses were incorrectly reported. For eyes randomized to receive afibercept, 163 were included in the per-protocol analysis for the key anatomical outcome and 106 were included in the per-protocol analysis for the visual acuity outcome. For eyes randomized to receive sham, 164 were included in the per-protocol analysis for the key anatomical outcome and 90 were included in the per-protocol analysis for the visual acuity outcome. This article was corrected online.

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editors: Jody W. Zylke, MD, Deputy Editor; Kristin Walter, MD, Senior Editor.